Abstract
The emergence of drug-resistant, multidrug-resistant and extensively drug-resistant tuberculosis (TB) is of major public health concern in several countries. In this study, the pharmacodynamic relationships among the structural analogs of antibiotics belonging to the same family were taken into consideration. The aim of this study was to compare the susceptibility of Mycobacterium tuberculosis to isoniazid (INH), rifampicin and levofloxacin (LX) to their respective structural analogs, which are frequently used as second-line agents. The microplate colorimetric method was used to determine the MIC to INH, ethionamide (ETH), rifampicin, rifabutin, LX and moxifloxacin (MOX) in clinical isolates previously shown to be drug resistant. Mutations conferring drug resistance were detected by GenoType MTBDR plus and DNA sequencing. INH and ETH cross-resistance was found in 95.12% (39/41) of the INH-resistant isolates harboring a mutation in inhAP or inhA open reading frame, but rifabutin cross-resistance was observed in 90.0% (63/70) of the clinical isolates originally shown to be resistant to rifampicin. Isolates with high LX-resistance levels also showed high MIC to MOX. Fluoroquinolone cross-resistance was verified in isolates containing the gyrA94 and the gyrA90 mutation. In general, isolates with high INH, rifampicin and LX-resistance levels also displayed high MIC values for their structural analogs. These findings suggest the need to test in vitro the second-line drugs before their incorporation in the therapeutic schemes.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
WHO Global Tuberculosis Control (2009) WHO/HTM/TB/2009.407.
WHO Global Tuberculosis Report (2012) WHO/HTM/TB/2012.6.
WHO Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response (2010) WHO/HTM/TB/2010.3.
Traore, H., Fissette, K., Bastian, I., Devleeschouwer, M. & Portaels, F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug-resistance. Int. J. Tuberc. Lung Dis. 4, 481–484 (2000).
Hoek, K. G. et al. Fluorometric assay for testing rifampin susceptibility of Mycobacterium tuberculosis complex. J. Clin. Microbiol. 46, 1369–1373 (2008).
Telenti, A. et al. Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 341, 647–650 (1993).
Morcillo, N. et al. A low cost, home-made, reverse-line blot hybridization assay for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 6, 959–965 (2002).
Mokrousov, I. et al. Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolates. J. Microbiol. Methods 57, 323–335 (2004).
Caws, M. et al. Mutations prevalent among rifampin and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J. Clin. Microbiol. 44, 2333–2337 (2006).
Ramaswamy, S. & Musser, J. M. Molecular genetics basis of antimicrobial agent resistance in Mycobacterium tuberculosis. 1998 Update. Tuber. Lung Dis. 79, 3–29 (1998).
Huitric, E., Werngren, J., Juréen, P. & Hoffner, S. Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant M. tuberculosis mutants. Antimicrob. Agent Chemother. 50, 2860–2862 (2006).
Moghazeh, S. L. et al. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 40, 2655–2657 (1996).
Taniguchi, H. et al. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol. Lett. 144, 103–108 (1996).
Ohno, H., Koga, H., Kohno, S., Tashiro, T. & Hara, K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob. Agents Chemother. 40, 1053–1056 (1996).
Almeida Da Silva, P. E. & Palomino, J. C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 66, 1417–1430 (2011).
Heym, B., Saint-Joanis, B. & Cole, S. T. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tubercle Lung Dis. 74, 267–271 (1999).
Saint-Joanis, B. et al. Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis. Biochem. J. 338, 753–760 (1999).
Hazbón, M. et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50, 2640–2649 (2006).
Kiepiela, P., Bishop, K. S., Smith, A. N., Roux, L. & York, D. F. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tubercle Lung Dis. 80, 47–56 (2000).
Rozwarsky, D., Grant, G., Barton, D., Jacobs, W. R. Jr. & Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279, 98–102 (1998).
Giannoni, F. et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 9, 2928–2933 (2005).
Pitaksajjakul, P. et al. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J. Trop. Med. Public Health 36 (Suppl 4), 228–237 (2005).
Ginsburg, A. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob. Agents Chemother. 49, 3977–3979 (2005).
Lee, A. S., Tang, L. L., Lim, I. H. & Wong, S. Y. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int. J. Infect. Dis. 6, 48–51 (2002).
Almeida da Silva, P., Von Groll, A. & Martin, A. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. Immunol. Med. Microbiol. 63, 1–9 (2011).
Imperiale, B., Cataldi, A. & Morcillo, N. Rapid detection of multidrug-resistant Mycobacterium tuberculosis by multiplex allele-specific polymerase chain reaction. Int. J. Tuberc. Lung Dis. 15, 496–501 (2011).
Imperiale, B. et al. First evaluation in Argentina of the GenoType®MTBDRplus assay for multidrug-resistant Mycobacterium tuberculosis detection from, clinical isolates and specimens. Rev. Argent. Microbiol. 44, 283–289 (2012).
Morcillo, N., Imperiale, B. & Di Giulio, B. Evaluation of MGIT 960 and the colorimetric-based method for tuberculosis drug susceptibility testing. Int. J. Tuberc. Lung Dis. 14, 1169–1175 (2010).
Martin, A. et al. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int. J. Tuberc. Lung Dis. 9, 901–906 (2005).
Morcillo, N. et al. A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents. Int. J. Tuberc. Lung Dis. 8, 253–259 (2004).
Morlock, G. P., Metchock, B., Sikes, D., Crawford, J. T. & Cookasey, R. C. EthA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 47, 3799–3805 (2003).
Williams, D. L. et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42, 1853–1857 (1998).
Acknowledgements
We thank Marcelo Mazza and Guillermo Alonso for their technical assistance. AC is a fellow and BI has a fellowship from the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) in Argentina. This work was partly financed by the FAST-XDR Project of the European Commission, FP7, CE: 201690.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Imperiale, B., Di Giulio, Á., Adrián Cataldi, Á. et al. Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs. J Antibiot 67, 749–754 (2014). https://doi.org/10.1038/ja.2014.61
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2014.61
This article is cited by
-
In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
The Journal of Antibiotics (2024)
